Please assess the completion status of the following clinical trial:

Trial Title: Reliability, Safety and Usability of the Transplantation Sensor System Combined With Myfortic® in Adult Kidney Transplant Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients at least 6 months post-transplantation and in stable clinical condition~* Treatment with ECMPS doses between 720 mg/day and 1440 mg/day or MMF doses between1000 mg/day and 2000 mg/day, divided in two equal doses 12 hours apart and with no dose titrations planned for the duration of the trial~* Ability to independently take medication~* Successfully ingest a Placebo-IEM capsule with no difficulty~Exclusion Criteria:~* Inability to use the mobile phone provided for use in the clinical trial~* Any episodes of acute rejection in the previous 3 months~* Presence of cognitive impairment~* Active alcohol or drug abuse~* History of dysphagia, or inflammatory bowel disease, or gastrointestinal conditions or surgery that has modified the normal luminal flow of the gastrointestinal tract (e.g. Whipple procedure, bariatric surgery or Roux-en-Y)~* Known allergies, including history of skin reactions to patches, that could preclude safe participation in the study Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ECMPS-IEM (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).